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Abstract. Neural crest-derived cells populate the thy- 
mus, and their coexistence with epithelial cells is re- 
quired for proper organ development and T cell educa- 
tion function. We show here that epidermal growth 
factor (EGF), a major epithelial cell growth-enhancing 
agent, has a morphogenetic action to promote the ex- 
pression of a neuronal phenotype (e.g., neurofilament 
expression) in cultured thymic epithelial cells that are 
characterized by a cytokeratin-positive epithelial cell 
background. The proliferation of such neurodifferenti- 
ated cells is also enhanced by EGF. Furthermore, the 
growth factor enhances cells that express the genes en- 
coding the preprotachykinin A-generated neuropep- 
tides and the bipotential neuropoietic and lymphopoi- 
etic cytokines ciliary neurotrophic factor and 
interleukin-6. These cytokines also enhance the neu- 
ronal phenotype of thymic epithelial cells. Therefore, 
EGF appears to be a composite autocrine/paracrine 
neuromodulator in thymic stroma. This suggests that 
EGF may regulate thymus-dependent immune func- 
tions by promoting neuronal gene expression in neural 
crest-derived cells. 
M 
ULTIPLE cell interactions control developmental 
cell  fate  and  morphogenesis.  The  morphoge- 
netic  process  of the  thymus  is  an  example  in 
which the variety of phenotypes resulting from T lymphoid 
cell developmental pathways and the acquisition of either 
the ability to react to external antigens  or the tolerance 
against self-antigens arise through the action of instructive 
and/or  selective differentiation  signals  generated  by the 
thymic stroma in close association with precursor and dif- 
ferentiating lymphoid cells (8, 47, 51). A striking  aspect of 
the thymic stroma is the coexistence of cell types arising 
from distinct cell lineages represented mainly by the endo- 
derm of the third pharyngeal pouch, the ectoderm of the 
third branchial cleft and cells from the corresponding re- 
gion of the neural crest (35, 36). The interaction of neuro- 
ectoderm-derived cells with other epithelial cells is neces- 
sary  for  both  the  organ  morphogenic  and  the  T  cell 
differentiation processes. Indeed, ablation of the cephalic 
neural crest in chicken embryos results in thymic aplasia/ 
hypoplasia (4, 7). The further fate and specific functions of 
neural crest-derived cells within the thymic stroma remain 
unclear, although the presence of neural crest-derived cells 
in thymic medulla and the expression of a number of neu- 
ronal markers  and neuropeptides in both thymic epithe- 
lium in vivo (14, 18, 20, 42) and thymic stromal cell cultures 
(50)  have been described.  Cytokeratin-harboring  thymic 
nurse epithelial cells also express most of these neuron and 
neuroendocrine markers and neuropeptides (19). 
The coexistence of epithelial and neural cells within the 
thymic stroma raises the question as to the nature of the 
regulatory  signals  that  determine  the  development  and 
survival of the neuronal component. EGF is a likely candi- 
date as a soluble regulatory signal.  Indeed, in addition to 
being  a  potent  growth  factor  for  several  epithelial  cell 
types (10), EGF and its receptor are expressed in the cen- 
tral nervous system (CNS)  1 (15, 21) and the growth factor 
promotes both neuron  survival and  mitogenesis  of neu- 
ronal  progenitors  derived  from  neonatal  rat  retina  and 
adult mouse striatum (1, 41, 45, 59). Furthermore, EGF re- 
ceptor ligands  (EGF  and  TGFet)  are  also expressed by 
thymic tissue in vivo and by human thymic epithelial cell 
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several cytokines (including interleukin-6 [IL-6]) (25, 32). 
The ability of EGF to enhance IL-6 production is of par- 
ticular interest. IL-6 belongs to the neuropoietic cytokine 
family that influences the survival, proliferation, and dif- 
ferentiation  of  neurons  (12,  24).  We  have  previously 
shown that IL-6 is able to enhance the neural phenotype 
of thymic stromal cells (50). The aim of this work is there- 
fore to study the role of EGF in regulating the neural cell 
population  in  thymic stroma  and  the  neurotrophic  mi- 
croenvironment sustained by these cells. 
Material and Methods 
Thymic Stromal Cell Cultures 
Several murine thymic stromal cell (TC) cultures were independently es- 
tablished from 4-5-wk-old C57BL/6 mice as previously described (38, 50). 
Human thymic stromal cell (HTC)  cultures were also independently es- 
tablished  from thymuses  of children  undergoing  cardiac  surgery.  Cells 
were cultured  in RPMI 1640 medium supplemented with 10% FCS and 
0.1 mg/ml sodium pyruvate and antibiotics (Hyclonc Europe Ltd., Cram- 
lington, UK). All experiments reported were performed with TC cultures 
from the 3rd to 40th passage. 
Flow Cytometry and Cell Cycle Analysis 
Cell cycle analysis was performed by fixing 1 x 106 control or 48 h EGF- 
treated cells in 70% cold ethanol for 30 min at 4°C and adding, after two 
washes in cold PBS, 0.5 mg/ml RNAse (Sigma Chemicals Co., St. Louis, 
MO), and 40 Ixg/ml of propidium iodide (Sigma). Cells were then kept in 
the dark at 4°C for 30 min and immediately analyzed by flow cytometry. 
The propidium iodide fluorescence emission, due to DNA content of indi- 
vidual cells, was filtered  through  a 585/42-nm band pass filter and mea- 
sured on a linear  scale using a FACScan cytometer (Becton Dickinson, 
Mountain View, CA). Cell debris and doublets were excluded from analy- 
sis by appropriate gating using physical parameters. 
Immunofluorescence and Immunoperoxidase Staining 
Immunofluorescence  staining was performed using cells grown on slide 
culture chambers, in the absence or presence of 10 ng/ml of EGF (Collab- 
orative  Res.  Inc.,  Bedford, MA), 0.5  ng/ml  recombinant murine IL-6 
(British Biotechnology, Oxford, UK), or 10 ng/ml recombinant rat ciliary 
neurotrophic factor (CNTF; Genzyme, Cambridge, MA). After washing 
with PBS, cells were immediately fixed with ice-cold absolute ethanol for 
5 rain and incubated with various primary polyclonal or monoclonal anti- 
bodies for 1 h at room temperature, washed  with PBS, and then incu- 
bated with Fluorescein (FITC)-conjugated goat anti-rabbit or anti-mouse 
(Fab') IgG (Sigma) for 45 rain at room temperature. For EGF receptor 
staining, cells were preincubated for 2 h in medium without FCS and then 
fixed with 2%  buffered paraformaldehyde  for 10 min at room tempera- 
ture.  Primary  antibodies  used included  polyclonal rabbit anti-EGF and 
anti-EGF receptor (Oncogene Science, Manhasset, NY), monoclonal anti- 
tyrosine hydroxylase (clone 2/40/15) and anti-neurofilaments  (NF) 200 kD 
(clone NE14) (both from Boehringer Mannheim GmbH, Mannheim, Ger- 
many),  anti-NF  160 kD (Amersham Corp., Buckingamshire,  UK), pan- 
cytokeratin  monoclonal  antibody  (clone  LU5,  Boehringer Mannheim 
GmbH), rabbit  polyclonal anti-synapsin  I antiserum  (a gift from P. De 
Camilli, Yale University School of Medicine, New Haven, CT), and mono- 
clonal anti-CNTF (Boehringer). 
Double-immunofluorescence  staining was performed by labeling cells 
with anti-cytokeratin  monoclonal antibody followed by fluorescein-conju- 
gated goat anti-mouse IgG and then with anti-NF  200 kD rabbit poly- 
clonal  antibody (Sigma) followed by rhodamine-conjugated  anti-rabbit 
IgG (ICN ImmunoBiologicals, Lisle, IL). Fluorescent images were ana- 
lyzed with a fluorescence microscope (DMRB; Leitz, Wetzlar, Germany) 
or a confocal laser scanning microscope (TCS 4D; Leica, Inc., Deerfield, 
IL). In the latter case, the green (FITC) and the red (rhodamine)  fluores- 
cences were independently recorded and elaborated through a 3-D func- 
tion (Extended Focus or Shadow Forming Projection). The 3-D-obtained 
images were then independently observed or electromcally superimposed 
to simultaneously demonstrate the double staining. 
Figure 1. Expression of EGF 
and  EGF receptor in  TC-1S 
cells  and  thymic  tissue.  (A) 
Fluorescence  photomicro- 
graph of cells immunoreactive 
for EGF.  (B)  RNA  isolated 
from  mouse  submaxillary 
glands  or  thymus  or  TC-1S 
cells  was  processed for  RT- 
PCR  using  either  EGF  or 
[3-actin  primers as  described. 
Results are shown as ethidium 
bromide staining of amplified 
products. RT-PCR reaction of 
the last lane does not contain 
RNA.  (C)  Scatchard plot  of 
I125-EGF  binding  to  TC-1S 
cells. (D and E) Immunoper- 
oxidase  staining  of  murine 
thymic  sections showing im- 
munoreactive EGF receptors 
(D)  and  EGF  (E)  (arrow- 
heads). 
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sham Cell Proliferation  kit (Amersham Corp.) according to the manufac- 
turer's instructions. Briefly, the cells were incubated for 1 h at 37°C with 
5'-bromo-2'-deoxyuridine  and 5'-fluoro-2'-deoxyuridine  and then fixed in 
90% ethanol/5%  acetic acid, rehydrated with PBS and stained with anti- 
BrdU antibody and then revealed with peroxidase-anti-mouse  IgG2a and 
diaminobenzidine intensified with cobalt chloride and nickel chloride. NF 
staining was demonstrated by immunoperoxidase  staining using anti-NF- 
200  kD  antibody  and  a  streptavidin-biotin  system  (Histostain  SP  kit; 
Zymed).  Ceils were counterstained with hematoxylin.  Substance  P was 
detected by irnmunoperoxidase  staining as described above. Cryostat tis- 
sue  sections from mouse thymus were stained using anti-EGF or anti- 
EGF receptor antibodies by immunoperoxidase  staining. 
Reverse Transcription Polymerase Chain Reaction 
and Northern Blot Analysis 
Reverse transcription polymerase chain reaction (RT-PCR) was performed 
by a first step of reverse transcription from DNaseI-treated  RNA isolated 
from TC-1S cells and brain for 15 min at 42°C, followed by 5 min at 99°C 
and then 5 rain at 5°C (GeneAmp RNA PCR Kit in a 20-p,1 vol containing 5 
mM MgC12, 2 ~1 PCR buffer, 1 mM each deoxynucleotide, 1 U RNase in- 
hibitor, 2.5 U Reverse Transcriptase; Perkin-Elmer  Cetus Corp., Norwalk, 
CF). Amplification of synthesized cDNA was then performed  using specific 
sense and antisense primers described below and reagents of the GeneAmp 
RNA PCR Kit in a 100-p.1 reaction volume. Each sample was overlaid with 
50 Ixl of mineral oil (Sigma) and incubated in a DNA thermal cycler control- 
ler. PCR products  were analyzed by 2% agarose gel eleetrophoresis fol- 
lowed by either ethidium bromide staining or Southern blotting and hybrid- 
ization using specific oligomers internal to the amplified sequences. 13-actin 
amplification using 5'-GTGGGCCGCTCTAGGCACCAA-3'  and 5'-CTC- 
TI'TGATGTCACGCACGATI'TC-3'  as 5' and 3' primers, served as an in- 
ternai  control for both reverse transcription  and the PCR. The 5' and 3' 
CNTF primers were 5'-CCAGTGGCAAGCACTGATC-3' and 5'-CCC- 
ATAATGGCI'CFCAAGTGC-3', respectively. The 5' and 3' CNTF-Rc~ 
primers  were  5'-GCTGTCACATTCGGTACATGC-3'  and 5'-AGCCA- 
CACTCCAGTCACTCCA-3',  respectively. The 5' and 3' IL-6-Ra primers 
were 5'-TTCATGATGCCTTGCGAGGA-3'  and 5'-TCATAAGGGC- 
TCTGTGCGTC-3',  respectively.  The  5'  and  3'  PPT-A primers were 
5'-AGCGACCAGATCAAGGAGG-3'  and  5'-GCACTCCTITCAT- 
AAGCCAC-3', respectively. The 5' and 3' EGF primers were 5'-TGTGT- 
TATI'GGCTATrCrGG-3'  and 5'-TCTFGGGGTCITGGTGT1TCT-3', 
respectively. Amplified fragments were hybridized with the following spe- 
cific internal sequences: 5'-TTGAGGCTGATACATCGACTGAACATC- 
AAT-3' (for CNTF-R¢0; 5'-ATGTGGGCAGGGACATGGACGAGGA- 
TrCTF-3' (for IL-6-Rc  0. Bands were quantitated by scanning densitometry 
using a GS-670 scanning densitometer (Bio-Rad Labs., Richmond, CA) and 
employing Molecular Analyst PC  TM software. 
Results 
EGF and EGF Receptor Expression in Cultured Thymic 
Epithelial Cells and in Thymic Tissue 
We have established and previously characterized several 
thymic  epithelial  cell  lines  (TC)  that  are  mostly  repre- 
sented by cytokeratin-positive epithelial cells that are able 
to support thymocyte  differentiation (38, 50). These lines 
also contain a minor NGF-sensitive neural cell population, 
which express synapsin-I and neuron-specific cytoskeletal 
neurofilaments (50). 
The existence of an autocrine/paracrine  loop involving 
EGF in TC cultures was suggested by immunofluorescent 
staining  of intracytoplasmic  EGF  in  ~25%  of the  cells 
(Fig. 1 A) and by the presence of EGF mRNA (Fig. 1 B). 
Furthermore, cell surface EGF receptors were observed in 
~50%  of the cells, as revealed by anti-EGF receptor im- 
munofluorescence  staining  (not  shown).  These receptors 
bound  125I-EGF with a  Kd of 0.74  ----- 0.1  nM  and  had  a 
concentration of 35,000  +_  3,000 sites/cell (Fig. 1 C). The 
production of EGF was confirmed in thymic tissue ex vivo 
which expresses EGF mRNA (Fig. i  B). Immunostaining 
for both EGF receptor (Fig. 1 D) and EGF (Fig. 1 E) was 
observed in epithelial cells of thymic medulla and cortex 
from ex vivo tissues. 
EGF Enhances the Neuronal Phenotype of Thymic 
Epithelial Cells 
The addition of EGF to several murine or human TC cul- 
tures  was  able  to  enhance  their  neuronal  phenotype  by 
Figure 2. (,4) Enhancement of NF mRNA levels by EGF. Total RNA was isolated from TC-1S cells, untreated or treated for 48 h with 
EGF and processed for Northern blot analysis as previously described (12)  using a  NF-160 kD  (NF-M)-specific 32p-labeled probe 
(pNf36; American Type Culture  Collection) (top)  and, after stripping, a  13-actin probe (bottom).  28S rRNA and the 3.5-kb NF-M 
mRNA are indicated. (B) Time course of EGF activity on the percentage of neurofilament-positive  cells relative to the total TC-1S cell 
population. (C) Percentage of neurofilament-positive  cells relative to the total cell population in the absence of EGF (-  EGF) or 48 h 
after the addition of the growth factor (+ EGF) in several murine TC cultures, 
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phenotype of TC-1S cells un- 
treated  (a.  b,  e,  and  f)  or 
treated with EGF for 48 h (c, 
d, h, and i). Phase contrast (a 
and c) and fluorescence  pho- 
tomicrographs of cells immu- 
noreactive  for  neurofila- 
ments (b and d), synapsin I (e 
and h) and tyrosine hydroxy- 
lase  (f and  i).  Fluorescence 
micrographs  of  human  TC 
cultures  immunoreactive for 
neurofilaments  in  the  ab- 
sence  (g) or in the presence 
of EGF treatment (j). Immu- 
noreactive cells display  long 
and fine processes. 
significantly increasing the levels of NF mRNA and both 
160- and 200-kD NF immunofluorescent staining intensity 
(Figs. 2 A  and 3, b and d). 
The percentage of NF  + cells was also increased by EGF 
in several cultures from murine or human thymuses (Fig. 
2, B  and C and Table I). NF÷cells also showed significant 
elongation of neurite-like processes after EGF treatment 
(Fig. 3). Most of the TC-1S cells displayed a similar cyto- 
keratin expression under both basal conditions and follow- 
ing EGF-treatment. This suggests an overlapping of cyto- 
keratin-positive  and  NF  +  cells.  NF  expression  has  been 
recently reported  to  be  confined  to  cytokeratin-positive 
epithelial cells in thymic neoplasms derived from cortical 
epithelium  of the  thymus  (37).  Therefore,  to  study  the 
relationships  between  the  EGF-induced  increase  in  NF 
expression  and  cytokeratin÷-epithelial  cells,  we  double- 
stained TC-1S cells with anti-cytokeratin and anti-NF anti- 
bodies. Figs. 4, b and c and 5, a and b show that NF expres- 
sion was only observed in cytokeratin-positive cells.  It is 
also  evident  from Figs.  4  and  5  that,  while  cytokeratin 
maintains  the  same paranuclear  localization in  both  un- 
treated and EGF-treated cells, the EGF-induced increase 
of NF expression is mainly evident in the cell periphery, 
along the  cytoplasmic processes.  EGF increased  NF  ex- 
pression in ~70%  of the cells which also coexpressed cy- 
tokeratin (Figs. 4, e and f  and 5, c and d), while we have 
been  unable  to  detect  NF  in  cytokeratin-negative  cells. 
This suggests an EGF-mediated enhancement of the neu- 
ral phenotype within the epithelial cell population itself. 
Table L Percent (Mean  +--  SD) of NF or TH-positive or 
SYN-positive Cells in Human TC Cultures before (Control) 
and after EGF Treatment 
Control  EGF 
Human cell 
line  NF  TH  SYN  NF  TH  SYN 
HTC-3  22  ±  3  10  ±  3  5  ---  1  60  ±  7  40  ±  8  10  ±  2 
HTC-14  20  ±  2  10  ---  2  8  ±-  3  65  ±  9  35  ±  5  20  ---  3 
HTC-16  21  +--  2.2  8  ±  1.5  5  "4-  1.5  57  ±  5  20  ±  4  25  ±  4 
HTC-19  16  ±  1.5  5  ±  2  4  ±  1  48  --+  6.2  20  ±  4  10  ---  3 
The Journal of Cell Biology, Volume 130, 1995  186 Figure 4. Phase contrast micrographs (a and d) and double immunofluorescence staining (b, c, e, and f) of TC-1S cells untreated (a-c) or 
treated for 48 h with EGF (d-f). TC-1S cells were stained with anti-cytokeratin (b and e) and anti-neurofilament (c and f) antibodies. 
EGF  also  enhanced  the  expression  of  other  markers 
specific for neuronal  and/or neuroendocrine  cells includ- 
ing synapsin 1 and tyrosine hydroxylase (TH)  (Fig. 3, e, f, 
h,  and  i).  The  percentage  of TH +  cells  increased  from 
9  _+  2%  to  35  _  4%  and  that  of synapsin  ÷  (Syn)  cells 
from 7  ---  2%  up to 30  +  6%, 48 h  after the addition of 
EGF. Similar results were observed in human thymic epi- 
thelial cells (Fig. 3, g and j and Table I). 
To  study whether the EGF-induced increase of neural 
cell number in TC cultures was due to an enhanced prolif- 
eration rate of NF  + cells, we analyzed the effect of EGF 
on TC-1S cell growth.  Cell cycle analysis showed that an 
increased percentage of cells were in S  and G2/M phases 
24  h  after EGF  treatment compared to untreated TC-1S 
(Fig. 6 A). Moreover, labeling TC-1S cells with BrdU and 
double  staining  with  anti-NF  and  anti-BrdU  antibodies 
Figure 5. Double immunoflu- 
orescence staining of TC-1S 
cells untreated  (a  and b) or 
treated for 48 h with EGF (c 
and  d).  TC-1S  cells  were 
stained with anti-cytokeratin 
(green  fluorescence)  and 
anti-NF  (red  fluorescence) 
antibodies  and  analyzed 
with  a  confocal  laser  scan- 
ning microscope, a shows the 
double  fluorescence  photo- 
micrograph  of  cytokeratin- 
positive TC-1S  cells, one  of 
which also coexpresses neu- 
rofilaments (arrow). The  ar- 
row  indicates  the  region  of 
the  cell  where  cytokeratin 
and  neurofilaments  coexist 
and are overlapping, b shows 
the  NF  immunoreactivity 
alone of the  same cell indi- 
cated by the  arrow  in  a.  (c 
and  d)  Simultaneous  repre- 
sentation of double immuno- 
fluorescence  staining  show- 
ing  cells  which  coexpress 
cytokeratin and neurofilaments that are distributed in distinct (separated green and red signals) or overlapping (yellow) regions. In c, cy- 
tokeratin appears to be localized in the perinuclear area while neurofilaments are mostly expressed along cytoplasmic processes, d indi- 
cates a cell displaying a neurite-like process harboring neurofilament immunoreactivity and both neurofilament and cytokeratin coex- 
pression in the cell body. 
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showed  that  EGF  addition  resulted  in  a  significant  in- 
crease of the percentage of NF  ÷ ceils incorporating BrdU 
(Fig. 6 B). This suggests that EGF enhances the prolifera- 
tion rate of NF  ÷ cells. 
Effect of  EGF on Neuropeptide  Production  by Thymic 
Epithelial  Cells 
To study whether the EGF-induced neurotypic response in 
thymic stroma  also  included the  ability to  influence the 
production of specific neurotransmitters, we  studied  the 
expression of the preprotachykinin A  (PPT-A) gene that 
encodes substance P and Neurokinin A. Scattered cells in 
thymic stroma have in fact been previously shown to ex- 
press both neuropeptides in vivo (14). We show here that 
TC-1S cells express the [3 and -/transcripts of the PPT-A 
gene (Fig. 7 A). The EGF-induced neurotypic response in 
thymic stroma included an increase of cells able to produce 
these PPT-A-derived neurotransmitters.  EGF induced a 
twofold and a sixfold increase of PPT-A mRNA levels (af- 
ter 4 and 24 h  of treatment, respectively, as evaluated by 
densitometric scanning) (Fig. 7 B). Furthermore, cells ex- 
pressing substance P  were barely detectable before EGF 
addition, following which substance P-expressing cells ac- 
counted for 25  _+  5 % of the total population (Fig. 7 C). 
Effect of EGF on Neuropoietic Cytokine Production 
Several neurotrophic and neuropoietic factors are able to 
enhance  the  neuronal  phenotype  and  neuropeptide  ex- 
pression. To study whether the EGF-induced neurotypic 
response  also  includes  specific neuropoietic factors,  we 
studied the ability of EGF to influence the expression of 
members of the neuropoietic cytokine family. Indeed, the 
previously reported ability of EGF to upregulate IL-6 ex- 
pression  in  human  thymic  epithelial  cells  (32),  makes 
members  of this  cytokine family (e.g.,  IL-6 and  CNTF) 
likely candidate targets of EGF regulation. Such cytokines 
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Figure 6. Effect of EGF on the growth rate of 
TC-1S cells. (A) Flow cytometry  cell cycle analy- 
sis of TC-1S cells untreated (control) or treated 
with EGF (+EGF) for 24 h. Numbers  indicate 
the percentage of cells in the G0/G1, S or G2/M 
phases of the cell cycle. (B) BrdU-labeled TC-1S 
cells  either  untreated  (-EGF)  or  treated 
(+EGF) for 24  h  with  EGF.  Results  are  ex- 
pressed as percentage of cells labeled with BrdU 
and/or anti-NF antibody. 
share  signal  transduction  coreceptor subunits  and  influ- 
ence both the immune and nervous systems since they are 
able  to  regulate  both  hemo-lymphopoiesis and  survival 
and differentiation of neurons  (12, 24). We first studied 
the expression of IL-6 and CNTF in TC-1S cells in the ab- 
sence of EGF treatment. Whereas IL-6 mRNA  was ob- 
served by Northern blot analysis (Fig. 8 D), CNTF tran- 
scripts were detectable only by increasing the sensitivity of 
the assay by the use of RT-PCR (Fig. 8 A). Similarly, only 
very low expression of CNTF protein was observed (2-4% 
of CNTF-immunoreactive cells). The presence of CNTF in 
thymic stromal  cells,  albeit  at  a  low level, was  striking, 
given the predominant expression of this cytokine in the 
astrocytes and Schwann cells of the peripheral and central 
nervous system  (16, 43,  56).  By using  RT-PCR,  we  ob- 
served that EGF significantly increased CNTF mRNA lev- 
els by threefold as early as 4 h after treatment with a fur- 
ther increase  (by 15-fold)  after 24  h  (Fig.  8  A  and  not 
shown). The EGF-induced enhancement of CNTF mRNA 
expression was also confirmed by Northern blot analysis 
using poly(A)+-selected cellular RNA, which showed sig- 
nificant expression of CNTF mRNA 24 h after EGF treat- 
ment (a 30-fold increase of CNTF mRNA levels compared 
to untreated cells) (Fig. 8 B). The percentage of CNTF- 
immunoreactive TC-1S cells was  also increased by EGF 
(22 +  3% of CNTF  ÷ cells 48 h after EGF-treatment) (Fig. 
8  C  and not shown). IL-6 gene expression was enhanced 
by EGF in murine TC-1S cells: IL-6 mRNA levels were in- 
creased by 15-fold and by 10-fold 1 and 24 h, respectively, 
after EGF treatment, compared to untreated cells (Fig. 8 
D and not shown). 
CNTF and IL-6 Enhance the Neuronal Phenotype of 
TC-1S Cells 
The enhanced expression of CNTF and IL-6 by EGF sug- 
gests  that  these  cytokines may contribute to  the  neuro- 
typic effect of this growth factor. IL-6 or CNTF activities 
have been previously reported to require the presence of 
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PPT-A  gene  expression  by 
EGF  in  TC-1S  cells.  (A) 
Southern  hybridization  of 
amplified  products  ob- 
tained by RT-PCR of PPT- 
A  gene transcripts in  RNA 
of TC-1S and mouse brain. 
Arrowheads indicate  [3  and 
~/  PPT-A  transcripts.  (B) 
Northern  blot  analysis  of 
PPT-A  mRNA  in  TC-1S 
cells untreated and 4 and 24 
h  after EGF  addition.  The 
5'-TAATCCAAAGAACT- 
GCTGAG-GCTYGGGTCT- 
3'oligonucleotide  (corre- 
sponding  to  the  substance-P 
encoding  region)  was  used 
as hybridization probe in both A and B. (C) Immunoperoxidase staining of TC-1S cells treated for 48 h with EGF describing cells 
with elongated processes showing immunoreactive substance P (arrowheads). 
at least two receptor subunits,  one of which is either the 
specific  IL-6-Ra  or  CNTF-Ret  subunit  and  the  other  a 
shared gpl30 signal transduction moiety (12, 24). We de- 
tected transcripts encoding both the o~ subunit of the IL-6 
and CNTF receptors in TC-1S cells (Fig. 9). Furthermore, 
we  observed  that  treatment  of TC-1S  cells  with  either 
CNTF or IL-6 increased the number of NF  ÷ cells by 2.5-3 
fold, respectively (Fig.  10 A). Both IL-6 and CNTF were 
also able to increase NF mRNA levels (by 6-fold and 10- 
fold, respectively) (Fig. 10 B). 
Figure 8. Expression and modulation of CNTF and IL-6 in TC-1S 
cells. (A) RNA isolated from TC-1S cells cultured in the absence 
(control)  or in the presence of EGF for 24 h (+EGF) or from 
mouse brain was processed for RT-PCR using CNTF primers as 
described.  Samples of the PCR reactions were taken at multiple 
points throughout the CNTF amplification  (21, 24, 30, and 30 cy- 
cles), allowing the analysis of the product during the exponential 
phase of DNA amplification.  Brain CNTF was amplified for 30 
cycles. Results are shown as ethidium bromide staining of CNTF 
amplified products (upper panel) or Southern blot hybridization 
of [3-actin (lower panel). (B and D) poly(A)  + RNA isolated from 
untreated (control) or 24 h EGF-treated (+EGF) TC-1S cells or 
total RNA from mouse brain was processed for Northern blot 
analysis using a CNTF cDNA probe obtained from rat brain by 
RT-PCR (B) and murine IL-6 cDNA (56) (D) and,  after strip- 
ping, a [3-actin probe (lower panels). (C) Fluorescence  micropho- 
tograph of TC-1S cells immunoreactive for CNTF 24 h after EGF 
treatment. 
Discussion 
The coexistence of migrating neural crest-derived elements 
or  cells  committed  to  the  neuronal  phenotype  together 
with distinct cell lineages appears to be widespread through- 
out several tissues (e.g., gut, thyroid, pancreas), including 
the  thymus  (2,  33,  34,  44).  Interestingly, in  this  organ  a 
tight link between epithelial and neural cell lineages has 
been suggested by the observation that neuronal cell cy- 
toskeletal  expression  is  confined  to  cytokeratin-positive 
epithelial cells in cortical-type epithelial thymomas (37). The 
coexpression of features characteristic of both epithelial and 
neuronal differentiation which has also been described in 
some  neuroendocrine  or  neuroectoderm-derived  tumors 
(6) suggests the existence of processes underlying epithe- 
lial-neural transition. The mechanisms involved in the reg- 
ulation  of these processes are likely to require  the  local 
production of factors with multifunetional properties with 
regard  to  neural  and  other  cell  lineage  trophisms.  The 
choice between the different cell fates may thus be defined 
by the balance of distinct  growth factors. This has been, 
for instance, described for NGF and glucocorticoids which 
have been previously reported to be the major regulators 
of the choice of the neural crest-derived cells towards the 
endocrine or sympathetic neuronal fate (reviewed in refer- 
ence 2). 
The involvement of EGF-like-related signals in deter- 
mining the  choices  between neuronal  and  epithelial  cell 
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TC-1S cells. RT-PCR of CNTFR~x and IL-6Ret transcripts  in 
RNA from TC-1S cells and mouse brain. Negative control with 
no RNA added to the RT-PCR reaction is also shown. Southern 
hybridization  of amplified products  using the described  30-mer 
internal  probes is shown. Ethidium  bromide staining of [5-actin 
amplification, as an internal control, is also shown. 
fate is suggested by the ability of the Drosophila Notch 
gene product, which harbors sequence elements homolo- 
gous to a region of EGF, to segregate epidermal and neu- 
ronal  lineages  from  the  ventral  neuroectoderm  and  to 
further  regulate  the  coexistence of both  cell  types  (re- 
viewed in 3). 
In this paper we report that EGF itself is able to control 
epithelial-neural cell relationships, as it behaves as a ma- 
jor autocrine and/or paracrine enhancer of neural cell type 
distribution in several thymic epithelial cell cultures. We 
also show that EGF was  able  to promote a  multivalent 
neurotypic response characterized by (a) increased prolif- 
eration  and  differentiation of cells  expressing  neuronal 
phenotype; (b)  enhancement  of cells  with  specific neu- 
ronal function (e.g., expression of substance P neurotrans- 
mitter); and (c) enhancement of specific neurotrophic fac- 
tors. Thus we confirm the recently reported neuropoietic 
effect of EGF on neuronal precursors of the CNS (45, 59) 
and extend these observations to include an effect on dis- 
tinct cell lineages. The ability of EGF to promote both the 
proliferation and the neuronal differentiation we have ob- 
served in thymic epithelial cells, is similar to the effects on 
ceils  of the  sympathoadrenal lineage:  both  effects have 
been, in fact, described in rat pheochromocytoma PC12 
cells (26, 40). The neuropoietic potential of EGF has been 
also observed on cells at a less differentiated stage, as neu- 
ronal  differentiation of undifferentiated  P19  embryonal 
carcinoma cells, in response to this growth factor, has been 
reported (13). 
We have further characterized the EGF response with 
regard  to  neuropeptide  and  neurotrophic factor regula- 
tion. One  of the most striking aspects of our study con- 
cerns the EGF-mediated modulation of CNTF and IL-6 
expression in  thymic epithelial  cells  and  their  potential 
role in contributing, together with EGF, to neuropoiesis 
within this cell population. The contribution of IL-6 and 
CNTF to the neuropoietic activity of EGF was suggested 
by the early induction of these cytokines by EGF and the 
Figure 10. CNTF and IL-6 enhance neuronal phenotype in TC-1S 
cells. (A) Fluorescence microphotograph  of NF-immunoreactive 
TC-1S cells 48 h after either CNTF or IL-6 treatment. (B) North- 
ern blot analysis of NF-M mRNA levels in untreated TC-1S cells 
(control) and 48 h after either CNTF or IL-6 treatment. 
subsequent  enhancement  of  the  neural  phenotype.  In- 
deed, the addition of exogenous IL-6 and CNTF promoted 
the neural phenotype in thymic epithelial cell cultures. 
To our knowledge, CNTF regulation by EGF has not 
previously  been  reported.  Both  EGF  and  CNTF  and 
other gpl30-transducing signals have been reported to en- 
hance  the  same  cis-regulatory  elements  of  responsive 
genes through the activation of transacting nuclear factors 
belonging to the STAT family (17, 27, 48, 49, 53, 60). This, 
together with the observation that EGF regulates CNTF 
expression, suggests that both factors extensively interact 
at multiple levels. 
The  signals  that  modulate  CNTF  expression  remain 
largely unidentified. EGF, which enhances wound healing 
and tissue regeneration (10), may link such processes to 
CNTF  expression.  Indeed,  CNTF  prevents  retrograde 
neuronal death after axotomy and alteration of the levels 
of this cytokine have been reported during nerve degener- 
ation and regeneration (11, 22, 23, 28, 52). The presence of 
a functional CNTF/CNTF-receptor pathway and its possi- 
ble participation in the neuropoietic response induced by 
EGF,  extends the  panel  of CNTF target  cells and  is  in 
keeping with a more general role for this cytokine in the 
growth  control  and  maturation  of neuronal  precursors. 
This is further supported by the expression of CNTF and 
CNTF-Ra in embryonic tissues previously reported (29). 
The discovery of a functionally active neurotrophic mi- 
croenvironment within the thymus and the link between 
epithelial and neural cells are intriguing considering that 
relationships between the  nervous  and  immune  systems 
and their deregulation have been implicated in the patho- 
genesis of several autoimmune diseases (e.g., myasthenia 
gravis associated with thymic epithelial cell tumors and au- 
toimmunity against axons and other neural structures, in- 
sulin-dependent diabetes mellitus) (5, 30, 31, 37, 58). The 
neuromodulatory role  of EGF  in  the  thymus  reveals  a 
novel characteristic of this growth factor in the relation- 
ship between neural networks and the immune system. We 
suggest that EGF may play a critical role in directing thy- 
mic epithelial cells towards a  neural-oriented cell fate, a 
phenomenon characteristic of certain myasthenia gravis- 
associated thymomas (37). The growth factor might thus 
be  involved in  the  pathogenesis  of thymic epithelial tu- 
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Moreover, the EGF-regulated bipotential  neuro- and lym- 
phopoietic cytokines (CNTF and IL-6)  or the growth fac- 
tor itself might either directly influence thymic lymphoid 
cells or sustain  an  appropriate  intrathymic  neuronal cell 
population  and  neurotransmitter  production,  which  in 
turn may  affect  thymocyte development. In this respect, 
several  neurotransmitters  and  neuropeptides  (including 
norepinephrine,  acetylcholine and substance P) have been 
shown to regulate  the function of mature and developing 
lymphocytes  (9,  39,  46,  54).  Interestingly,  we  have  ob- 
served that EGF-treated thymic epithelial  cells reduce the 
ability of CD4-8-precursor thymocytes  to generate more 
mature  CD4+8 + T  cells in lympho-epithelial  cell  cocul- 
tures in vitro (our unpublished  data). Thus, the composite 
spectrum  of EGF activity  upon the thymus  suggests  that 
this organ may be the site at which a novel regulatory  ac- 
tivity  of the growth  factor  upon neural-immune  interac- 
tions could occur. 
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